

13 March 2024

Osteopore announces \$3m Entitlement Offer to strengthen balance sheet and support growth

Highlights

- 10-for-1 Renounceable Pro-Rata Entitlement Offer to raise approximately A\$3 million (before costs)
- Entitlement Offer to be made at an Offer Price of A\$0.029 per share
- With every 5 new shares subscribed, shareholders will receive one free-attaching option
- Shareholders can trade their rights, commencing 15 March 2024 for 6 business days, and can apply for additional shares with free attaching options.
- Funds raised will strengthen Osteopore's balance sheet and support the business to maintain sales momentum, continue developing and launching breakthrough products, secure regulatory clearances in new markets, advance M&A opportunities, and increase working capital

Singapore-founded regenerative medicine company **Osteopore Limited (ASX:OSX or the Company)** – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to announce a 10-for-1 Renounceable Pro-Rata Entitlement Offer at A\$0.029 per share to raise ~A\$3,000,000 (before costs)(**Entitlement Offer**).

The Entitlement Offer Price of A\$0.029 represents a discount of 94.42% to the Company's closing share price of \$0.52 on 12 March 2024. For every 5 new shares subscribed under the Entitlement Offer, shareholders will receive one free-attaching option at an exercise price of A\$0.0387, which will expire two years from the closing date of the Entitlement Offer.

The Entitlement Offer is open to all shareholders registered at 4.00 pm (WST) on 18 March 2024 (**Record Date**) whose registered address is in either Australia, New

Zealand, Malaysia or Singapore (**Eligible Shareholders**). Shareholders whose registered address is outside those countries as of the Record Date are deemed ineligible (**Ineligible Shareholders**).

The Entitlement Offer closes at 5.00 pm (WST) on 2 April 2024 (**Closing Date**). Pursuant to the Shortfall Offer, Eligible Shareholders may apply for unsubscribed New Shares in excess of their Entitlement – together with attaching options – on the same terms as the Entitlement Offer.

The Company's Directors who are current shareholders of Osteopore intend to wholly or partly participate in the Entitlement Offer.

The Company lodged a prospectus with ASIC on 13 March 2024 regarding the Offer (**Prospectus**). The Company believes the equitable non-dilutive nature of the Entitlement Offer allows shareholders to participate on attractive terms.

Purpose of the Entitlement Offer

Funds raised from the Entitlement Offer will be used to:

- (a) maintain sales momentum;
- (b) continue developing and launching breakthrough products;
- (c) secure regulatory clearances in new markets;
- (d) advance merger and acquisition (M&A) opportunities;
- (e) increase working capital; and
- (f) pay costs associated with the Offer.

Further details on the Company's intended use of the funds raised are set out in the Prospectus.



Indicative Timetable

The Offer – as defined in the Prospectus – will be undertaken in accordance with the indicative timetable below:

Event	Date
Prospectus Lodgement Date	13 March 2024
Announcement of Prospectus & Appendix 3B with ASX	13 March 2024
“Ex” date	15 March 2024
Rights start trading	15 March 2024
Record Date to determine Entitlements	18 March 2024
Prospectus with Application Form dispatched	19 March 2024
Entitlement Offer opens for receipt of Applications	19 March 2024
Rights trading ends at close of trading	22 March 2024
Securities quoted on a deferred settlement basis	25 March 2024
Last day to extend the Closing Date (before noon AEDT)	26 March 2024
Closing Date as at 5.00pm	2 April 2024
Announcement of results of the Entitlement Offer	5 April 2024
Issue of New Shares and New Options and lodgement of Appendix 2A with ASX applying for quotation of New Shares	8 April 2024
Quotation of New Shares issued under the Offer	9 April 2024
Issue of remaining Additional New Shares under Shortfall Offer (if any)	By no later than 3 months after the Closing Date

*Dates – other than the date of the Prospectus and the Prospectus Lodgement Date with ASIC and ASX – are indicative only. The Directors may decide to extend the



Closing Date of the Entitlement Offer by notifying ASX – a minimum of three business days – before the Closing Date. Subsequently, the date that the Securities are expected to commence trading may vary.

Rights Trading

The Entitlement Offer is renounceable which means that there will be trading of rights on the ASX and Eligible Shareholders may dispose of their entitlement to subscribe for New Shares and New Options under the Entitlement Offer to another party other than on the ASX. If you do not dispose of your entitlement during the rights trading period (ending on Friday 22 March 2024) or take up your entitlement by the Closing Date, your right to take your entitlement will lapse.

The securities in your entitlement that are not taken up by you, or any person that you dispose of your entitlement to, will form part of the Shortfall (as noted below). If you are an Eligible Shareholder and you wish to sell or transfer all or part of your entitlement to another person you should follow the directions in the Application Form and section 5.5 of the Prospectus.

Application for New Shares

Eligible Shareholders may apply for New Shares under the Entitlement Offer subject to such Applications being received by the Closing Date. Eligible Shareholders may also apply for New Shares exceeding their entitlements under the Shortfall Offer by completing the relevant section on the Application Form and paying the appropriate Application monies as per the instructions detailed in the Application Form.

Shortfall Offer

Shares not taken up under the Entitlement Offer (**Shortfall Securities**) may be issued by the Company to Eligible Shareholders within three months of the Closing Date.

The Offer Price for every New Share issued under the Shortfall Offer shall be A\$0.029, being the same price at which New Shares are issued under the Entitlement Offer. Participants in the Shortfall Offer will also receive one free-attaching option for every 5 new Shares subscribed under the Shortfall Offer.

Shortfall Securities will be allocated at the discretion of the Company as per the allocation policy outlined in Section 3.10 of the Prospectus. Subsequently, there is no guarantee that Eligible Shareholders will receive any Securities under the Shortfall Offer.



Consultant Fees

The Company has entered into a mandate with Advance Capital Partners Pte Ltd (**Advance Capital**) in connection with fund raising and general corporate advisory activities (the **Mandate**). In connection with the Mandate, Advance Capital will be entitled to a fee of up to A\$90,000 (being 3% of the proposed maximum subscription of A\$3,000,000) as a result of the Entitlement Offer (in the event the Entitlement Offer is fully subscribed).

Further details in respect of the Consultant's interests in the Company and the Offers are set out in section 8.7 of the Prospectus.

The Company has appointed ACNS Capital Markets Pty Ltd, trading as Alto Capital, as its nominee to sell the Entitlements of Ineligible Shareholders in accordance with section 9A(3) of the Corporations Act (the Nominee Appointment). In connection with the Nominee Appointment, the Company will pay the Nominee a fee of \$10,000 + GST. The Nominee Appointment is otherwise subject to terms and conditions standard for an agreement of its nature.

Prospectus

Details of the Entitlement Offer are contained within the Prospectus. A copy of the Prospectus will be e-lodged to the ASX via ASX Online together with this Announcement. The Prospectus is also available on the Company's website at www.osteopore.com/investors. The Directors of Osteopore encourage shareholders to read the Prospectus carefully and to seek independent advice from your financial adviser.

ENDS

This announcement dated 13 March 2024 has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Mark Leong

Executive Chairman

Osteopore Limited

T: +65 9011 7009

E: mark_leong@osteopore.com

Isaac Stewart

Media & Investor Relations

Cannings Purple

T: +61 423 306 795

E: istewart@canningspurple.com.au

About Osteopore Limited

Osteopore Limited is a Singapore-founded regenerative medicine company and a global leader in 3D-printed biomimetic and bioresorbable implants. The Company seeks to commercialise products that stimulate natural bone healing across multiple segments.



Osteopore creates patented scaffolds using 3D-printed biomimetic and bioresorbable materials to guide and nurture bone-forming cells.

Through our proprietary manufacturing process – which uses a naturally dissolving polymer – our patented scaffolds enable bone tissue growth, significantly reducing the post-surgery complications commonly associated with permanent bone implants.

Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are or may be, forward-looking statements.

Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Depending on several factors, actual results may differ materially from those expressed or implied by these forward-looking statements.

